2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (COMPLETED)2298 - Waratah - Calvary Mater Newcastle Medical Oncology (WITHDRAWN)

3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (COMPLETED)

NCT06064877

A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)

NCT06022029

A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas (ON-5001)

SA5042 - Bedford Park - Southern Oncology Clinical Research Unit (COMPLETED)

NCT06004245

A Phase I, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-Tumor Activity of VVD-133214 as Monotherapy and in Combination in Participants With Advanced Solid Tumors Harboring Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) (VVD-133214-01)

NCT05997615

A Phase 1, First-in-Human Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Participants With Prostate Cancer (VIR-5500-V101)

NCT05969041

MYE Symphony: A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors (MYE-Symphony)

NCT05939414

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC) (PSMA-DC)

NCT05894239

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer (INAVO122)

NSW2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (WITHDRAWN)2148 - Blacktown - Blacktown Hospital, Blacktown Cancer and Haematology Centre (WITHDRAWN)2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (WITHDRAWN)

VIC3168 - Clayton - Monash Medical Centre (COMPLETED)

WA6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (COMPLETED)

NANA (WITHDRAWN)

NCT05800665

A Phase 1, Open-Label, Multicenter, Dose-Escalation and Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 in Patients With Advanced or Metastatic Prostate Cancer (GO44537)

NCT05785754

A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors (DCSZ11-101)

2076 - Wahroonga - Sydney Adventist Hospital (WITHDRAWN)2170 - Liverpool - Liverpool Hospital (COMPLETED)

3144 - Malvern - Cabrini Health, Cabrini Cancer Care Centre (COMPLETED)

4556 - Buderim - Sunshine Coast Haematology and Oncology Clinic (WITHDRAWN)

NCT05759728

A Phase 1/2a, Multicenter, Open-Label, Dose Escalation and Expansion Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Adult Subjects With Metastatic Colorectal Cancer (CNA3103-001)

NCT05727176

Phase 2 Study of Futibatinib 20 mg and 16 mg in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusions or Rearrangements (FOENIX-CCA4)

NSW2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (COMPLETED)

VIC3004 - Melbourne, Southbank - Alfred Health (COMPLETED)

WA6008 - Subiaco - Bendat Family Comprehensive Cancer Centre - St John of God Subiaco Hospital (COMPLETED)

NCT05706129

A Multicenter, Open-Label, Non-Randomized Phase 1/2 Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Patients With Unresectable Locally Advanced or Metastatic Solid Tumors (ITM-9.4.1.1.01CT)

NCT05646862

A Phase III, Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Versus Alpelisib Plus Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Who Progressed During or After CDK4/6 Inhibitor and Endocrine Combination Therapy (INAVO121)

2250 - Gosford - Central Coast Cancer Centre, Gosford Hospital (COMPLETED)2560 - Campbelltown - Macarthur Cancer Therapy Centre - Campbelltown Hospital (WITHDRAWN)

QLD4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (COMPLETED)

NANA (WITHDRAWN)

NCT05633654

A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (GS-US-595-6184)

2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (WITHDRAWN)

NCT05614739

FORAGER-1: A Phase 1, Open-Label, Multicenter Study of Vepugratinib (LY3866288; LOXO-435) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer and Muscle Invasive Bladder Cancer With FGFR3 Alterations

NCT05458219

A Phase 1a/b, Multicenter, Open-label, First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors (CIBI343A101)

NCT05417594

A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1)

NCT05320198

RALLY-MF: A Phase 1b/2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of DISC-0974 in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia (DISC-0974-102)

NCT05303519

A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine in Participants With Isocitrate Dehydrogenase 1 (IDH1)-Mutant Glioma (SIGMA)

NCT05216432

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer (RLY-2608-101)

NCT04947189

4CAST: A Phase 1b Dose Exploration and Dose Expansion, Open-label, Single-centre Study Evaluating the Safety and Efficacy of INO-464 in Combination With Chemotherapy in Patients With metASTatic Breast Cancer

NCT04614103

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer (IOV-LUN-202)

NCT03522064

High Dose Testosterone + Carboplatin in Men With Advanced Prostate Cancer (HiTeCH)

ACTRN12626001252303

Not Applicable

A multi-centre pilot study of 3-fractIoN CEliac Plexus RadioablaTION (INCEPTION): Evaluating the efficacy in reducing pain in adults with pancreatic cancer and cancer-related abdominal pain caused by involvement of the celiac plexus

ACTRN12626000704392

A Bayesian Phase II study with toxicity monitoring of elranatamab monotherapy in newly diagnosed systemic light-chain (AL) amyloidosis (ENLIGHT)

ACTRN12626000207314

An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 Co-Administered with a CYP3A Inhibitor in Patients with Advanced KRAS Mutant Solid Tumors (TLN-372-2502)

ACTRN12626000034336

A single arm study of the effect of Androgen Receptor Pathway inhibition plus Adaptive-dosed [177Lu]Lu-PSMA-597 on PSA level in metastatic hormone sensitive prostate cancer (OPTIMAL-e)

ACTRN12625000971437

Dose Optimisation and PSMA Receptor intensification with 177Lu-PSMA Therapy in Patients Diagnosed with Metastatic Castrate Resistant Prostate Cancer : A Randomised Phase II trial: OPTIMAL-PSMA

ACTRN12625000964415

ALLG AMLM30/EVOLVE II: Randomised study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy (EVOLVE-II)

ACTRN12625000697482

A parallel-group, 2-arm, Phase 2, multisite, stratified, double-blind, randomised, study to investigate the safety and effectiveness of doxycycline or placebo in conjunction with standard of care in adults with metastatic adenocarcinoma of the lung undergoing targeted anti-cancer therapy. (DULCE)

ACTRN12624001458527

Randomised Phase 2 study of sphingosine kinase inhibitor (opaganib) in addition to darolutamide in people with poor prognostic metastatic castration resistant prostate cancer (mCRPC) based on a companion circulating lipid biomarker, PCPro (ANZUP2205) (DARO-LIPID)

ACTRN12624000582550

Evaluating the efficacy of bipolar androgen therapy in extending metastasis-free survival in patients with M0 castrate-resistant prostate cancer with prostate specific antigen progression but not radiological or clinical progression on darolutamide (WOMBAT) - ANZUP 2201

ACTRN12624000027516

Romosozumab for Patients with Multiple Myeloma with Skeletal Events on Zoledronic Acid: A Pilot Study

ACTRN12623000919617

A clinical trial exploring MR guided adaptive stereotactic radiotherapy boost to the prostate combined with stereotactic radiotherapy to the whole pelvis (MR-PROTEUS)

ACTRN12623000160639

A Randomized, Open-Label, Phase 2 Study of Darolutamide as Single Agent or in Combination with EPI-7386 as a Neoadjuvant Treatment for Patients Undergoing Prostatectomy for Localized Prostate Cancer (DaSCENT)

ACTRN12623000096651

LUMOS2: Low & Anaplastic Grade Glioma Umbrella Study of Molecular Guided TherapieS

ACTRN12622001478707

Not Applicable

A multi-centre, randomised phase 2 clinical trial of early salvage radiotherapy versus surveillance on the incidence of biochemical recurrence after radical prostatectomy for men with prostate cancer, incorporating clinical and imaging-based risk stratification. (DIPPER)

ACTRN12622001232729

A multi-centre phase II, Australian and New Zealand, exploratory study of amendments to conditioning regimens in haplo-identical stem cell transplantation (The-ANZHIT-2-study)

ACTRN12622001003763

A multi-centre, open label phase 2 trial investigating the effect of evolocumab in addition to chemotherapy or androgen receptor signalling inhibitor therapy on the circulating lipid profile of men with metastatic castration-resistant prostate cancer (X22-0072)

ACTRN12622000016730

Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously untreated HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study (HER2Pro-1B)

ACTRN12621001037897

An immune-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma incorporating Iberdomide, Isatuximab, and Dexamethasone (Iber-IsaDex) – the IBIS study (IBIS-Study)

ACTRN12621000951853

Not Applicable

Pilot Study of Fesability of Neoadjuvant Radiosurgery for Breast Cancer and Non-Small Cell Lung Cancer Intracranial Metastases (NEST-Trial)

ACTRN12621000611820

Prostate-Specific Membrane Antigen (PSMA) Intensity Can be Altered by Androgen and phospho-SrC Obstruction (PICAASO)

ACTRN12615000190505

Not Applicable

A pilot study: Risk adapted hypofractionated radiotherapy in Merkel Cell Carcinoma of the elderly and/or the fragile patient assessing safety/efficacy. (MP4-pilot-study.)

NCT04205227

A Phase 1/2A Trial of ENB 003 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors (MK3475-951)

PD-1/PD-L1	23%
PD-1	20%
oestrogen axis	12%
ER	9%
ERBB2	8%
androgen axis	8%
AR	7%
PSMA	7%
PI3Kalpha	7%
PD-L1	6%
TIGIT	6%
KRAS	6%
cereblon	5%
CDK4	5%
Trop2	4%
CDK6	4%
Bcl2	4%
CD38	3%
Nectin4	3%
CYP17A1	3%
CLDN18.2	3%
gp100	3%
VEGF	3%
DNA methyltransferase	3%
PARP	3%
proteasome	2%
BCMA	2%
PI3K delta	2%
VEGFA	2%
CDK4 selective	2%
KMT2A	2%
menin-MLL1	2%
menin	2%
LHRH	2%
PARP1-selective	2%
EGFR	2%
FGFR	2%
FGFR3	2%
HDAC6	1%
LSD1	1%
STEAP2	1%
CDK2	1%
ERBB3	1%
SMO	1%
IL-2	1%
AKT	1%
PIWIL1	1%
KAT6	1%
KAT6A	1%
DHFR	1%
HDAC	1%
ITK	1%
ER alpha	1%
GPC3	1%
DPD	1%
orotate phosphoribosyltransferase	1%
B7H3	1%
BRAF	1%
CRAF	1%
MEK	1%
RAF	1%
TGFBR2	1%
HGF	1%
STING	1%
WRN	1%
CD93	1%
LGR5	1%
FGFR1	1%
FGFR1/2/3	1%
FGFR2	1%
FGFR4	1%
CAIX	1%
IDH1	1%
IDH1 R132	1%
sphingosine kinase-2	1%
SOST	1%
antiandrogen,AR NTD	1%
CTLA4	1%
PI3K	1%
XPO1	1%
mTOR	1%
mTORC1	1%
mTORC2	1%
PCSK9	1%
BCR-ABL1	1%
KIT	1%
PDGFRA	1%
SRC	1%
YES1	1%
ETBR	1%

ARTICANZ - Beta (ver 0.91)

Search results

Filters